Article

Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1.

Departments of Obstetrics and Gynecology Biocehmistory, Shimane University School of Medicine, Izumo, Japan.
Journal of Obstetrics and Gynaecology Research (Impact Factor: 0.84). 07/2012; DOI: 10.1111/j.1447-0756.2012.01946.x
Source: PubMed
0 Bookmarks
 · 
50 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the most lethal gynecologic malignancy. Despite advances in chemotherapy, the five-year survival rate of advanced ovarian cancer patients with peritoneal metastasis remains around 30%. The most significant prognostic factor is stage, and most patients present at an advanced stage with peritoneal dissemination. There is often no clearly identifiable precursor lesion; therefore, the events leading to metastatic disease are poorly understood. This article reviews metastatic suppressor genes, the epithelial-mesenchymal transition (EMT), and the tumor microenvironment as they relate to ovarian cancer metastasis. Additionally, novel chemotherapeutic agents targeting the metastasis-related biochemical pathways are discussed.
    International Journal of Molecular Sciences 01/2012; 13(9):11705-17. · 2.46 Impact Factor